Geneva, April 28 -- International Clinical Trials Registry received information related to the study (NCT07537972) titled 'Denosumab Strategy for Liver Cancer With Bone Metastases' on April 12.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).
Primary Sponsor: Tongji Hospital
Condition:
Hepatocellular Carcinoma (HCC)
Bone Metastases
Intervention:
Drug: Denosumab
Drug: Sintilimab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: May 1, 2026
Target Sample Size: 50
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07537972
Disclaimer: Curate...